Maintenance versus no Maintenance BCG Immunotherapy of Superficial Bladder Cancer

100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19 [Review/Perspective]

N Lobo;N Brooks;A Zlotta;J Cirillo;S Boorjian;P Black;J Meeks;T Bivalacqua;P Gontero;G Steinberg;D McConkey;M Babjuk;J Witjes;A Kamat Nature Reviews Urology, Jun 15;1-12

PMid: PMID34131332 | PMC number: PMC8204595

The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer [Editorial]

R Li;SP Lerner;A Kamat European Urology Apr;79(4):437-439

PMid: PMID33454163

Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research [Review]

C Ryan Urologic Oncology: Seminars and Original Investigations, May;37(5):318-323; Jul 31 [Epub ahead of print]

PMid: PMID30072304

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Summary and recommendations from the National Cancer Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer

SP Lerner;DF Bajorin;CP Dinney;JA Efstathiou;S Groshen;NM Hahn;D Hansel;D Kwiatkowski;M O'Donnell;J Rosenberg;R Svatek;JS Abrams;H Al-Ahmadie;AB Apolo;J Bellmunt;M Callahan;EK Cha;C Drake;J Jarow;A Kamat;W Kim;M Knowles;B Mann;L Marchionni;D McConkey;L McShane;N Ramirez;A Sharabi;AH Sharpe;D Solit;CM Tangen;AT Amiri;E Van Allen;PJ West;JA Witjes;D Quale Bladder Cancer Apr 27;2(2):165-202

PMid: PMID27376138 | PMC number: PMC4927845

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer [PMC2695968; PMID18367117]

SP Lerner;CM Tangen;H Sucharew;DP Wood;ED Crawford Urologic Oncology 27(2):155-159

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Patterns of recurrence and outcomes following induction bacillus calmette-guerin for high risk Ta, T1 bladder cancer [PMID17437798]

SP Lerner;CM Tangen;H Sucharew;D Wood;ED Crawford Journal of Urology 177:1727-1731

Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 bladder cancer - a Southwest Oncology Group Trial

SP Lerner;C Tangen;H Sucharew;D Wood;ED Crawford Journal of Urology 171(Suppl 4):72(#273)

Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study

DL Lamm;BA Blumenstein;JD Crissman;JE Montie;JE Gottesman;BA Lowe;MF Sarosdy;RD Bohl;HB Grossman;TM Beck;JT Leimert;ED Crawford Journal of Urology 163:124-1129

Maintenance BCG immunotherapy: Evidence of additional protection against cancer. A Southwest Oncology Group study.

DL Lamm;JD Crissman;JE Montie;JE Gottesman;BA Lowe;MF Sarosdy;RD Bohl;HB Grossman;TM Beck;JT Leimert;ED Crawford;U Kosecka;RC Wittes Proc of the American Urological Association :#1464

Significant long-term patient benefit with BCG maintenance therapy: A Southwest Oncology Group study.

DL Lamm;B Blumenstein;M Sarosdy;HB Grossman;ED Crawford Journal of Urology 157(4)Suppl:213(#831)

Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study.

DL Lamm;ED Crawford;B Blumenstein;MF Sarosdy;HB Grossman;RD Bohl;B Lowe;TD Moon;WL Weems;TM Beck;J Montie;JA Smith;J Crissman;CA Coltman Jr ASCO 11:203(#627)